Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.…
Lifecore Biomedical: Q3 Earnings Snapshot
Lifecore Biomedical (NASDAQ: LFCR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 382 employees.
The shares were at 6.390 USD on 20 November 2026, down 6.7% over 52 weeks. Its 52-week range is 3.630 USD to 8.980 USD: the price is 28.8% below the high and 76.0% above the low.
Its market capitalisation is 242.22M USD.
Lifecore Biomedical reports return on equity of 272.6%, an operating margin of -6.2% and revenue down 18.6% year over year.
Its debt exceeds its cash by 139.14M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 2 analysts cover the stock, with an average rating of Hold; their mean price target of 6.280 USD is 1.7% below the current price. The next earnings report is expected on 24 February 2027.